综述 |
|
|
|
|
mRNA疫苗及其基于聚合物的递送系统研究进展* |
张亚茹1,王慧梅1,迟永杰2,高媛1,赵颖1,暴佳欣3,张竞2,王连艳2,**() |
1 东北林业大学化学化工与资源利用学院 哈尔滨 150040 2 中国科学院过程工程研究所 生化工程国家重点实验室 北京 100190 3 黑龙江中医药大学药学院 哈尔滨 150040 |
|
Research Progress of mRNA Vaccines and Polymer-based Delivery Systems |
ZHANG Ya-ru1,WANG Hui-mei1,CHI Yon-jie2,GAO Yuan1,ZHAO Ying1,BAO Jia-xin3,ZHANG Jin2,WANG Lian-yan2,**() |
1 College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University,Haerbin 150040, China 2 State Key Laboratory, Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China 3 College of Pharmacy, Heilongjiang University of Chinese Medicine, Haerbin 150040, China |
引用本文:
张亚茹, 王慧梅, 迟永杰, 高媛, 赵颖, 暴佳欣, 张竞, 王连艳. mRNA疫苗及其基于聚合物的递送系统研究进展*[J]. 中国生物工程杂志, 2023, 43(5): 55-68.
ZHANG Ya-ru, WANG Hui-mei, CHI Yon-jie, GAO Yuan, ZHAO Ying, BAO Jia-xin, ZHANG Jin, WANG Lian-yan. Research Progress of mRNA Vaccines and Polymer-based Delivery Systems. China Biotechnology, 2023, 43(5): 55-68.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2211043
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I5/55
|
[1] |
Pippa N, Gazouli M, Pispas S. Recent advances and future perspectives in polymer-based nanovaccines. Vaccines, 2021, 9(6): 558.
doi: 10.3390/vaccines9060558
|
[2] |
Scheiblhofer S, Thalhamer J, Weiss R. DNA and mRNA vaccination against allergies. Pediat Allergy and Immunology: Official Publication of the European Society of Pediatric Allergy and Immunology, 2018, 29(7): 679-688.
|
[3] |
Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biology, 2012, 9(11): 1319-1330.
doi: 10.4161/rna.22269
pmid: 23064118
|
[4] |
Pardi N, Hogan M J, Porter F W, et al. mRNA vaccines:a new era in vaccinology. Nature Reviews Drug Discovery, 2018, 17(4): 261-279.
doi: 10.1038/nrd.2017.243
|
[5] |
Linares-Fernández S, Lacroix C, Exposito J Y, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends in Molecular Medicine, 2020, 26(3): 311-323.
doi: S1471-4914(19)30244-8
pmid: 31699497
|
[6] |
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics:developing a new class of drugs. Nature Reviews Drug Discovery, 2014, 13(10): 759-780.
doi: 10.1038/nrd4278
pmid: 25233993
|
[7] |
王彧, 白岳丘, 田易晓, 等. mRNA疫苗在疾病预防与治疗中的研究进展与展望. 中国生物工程杂志, 2022, 42(10): 51-59.
|
|
Wang Y, Bai Y Q, Tian Y X, et al. Advances and prospects of mRNA vaccines used in the prevention and therapies of diseases. China Biotechnology, 2022, 42(10): 51-59.
|
[8] |
Richner J M, Himansu S, Dowd K A, et al. Modified mRNA vaccines protect against zika virus infection. Cell, 2017, 168(6): 1114-1125.e10.
doi: S0092-8674(17)30195-2
pmid: 28222903
|
[9] |
Chahal J S, Khan O F, Cooper C L, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113(29): E4133-E4142.
|
[10] |
Kose N, Fox J M, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Science Immunology, 2019, 4(35): eaaw6647.
|
[11] |
Alberer M, Gnad-Vogt U, Hong H S, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet, 2017, 390(10101): 1511-1520.
doi: 10.1016/S0140-6736(17)31665-3
|
[12] |
Chaudhary N, Weissman D, Whitehead K A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 2021, 20(11): 817-838.
doi: 10.1038/s41573-021-00283-5
pmid: 34433919
|
[13] |
Baeza Garcia A, Siu E, Sun T, et al. Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nature Communications, 2018, 9(1): 1-13.
doi: 10.1038/s41467-017-02088-w
|
[14] |
Maruggi G, Chiarot E, Giovani C, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine, 2017, 35(2): 361-368.
doi: S0264-410X(16)31101-X
pmid: 27939014
|
[15] |
Cordery D V, Kishore U, Kyes S, et al. Characterization of a Plasmodium falciparum macrophage-migration inhibitory factor homologue. The Journal of Infectious Diseases, 2007, 195(6): 905-912.
doi: 10.1086/522472
|
[16] |
Dobson S E, Augustijn K D, Brannigan J A, et al. The crystal structures of macrophage migration inhibitory factor from Plasmodium falciparum and Plasmodium berghei. Protein Science, 2009, 18(12): 2578-2591.
doi: 10.1002/pro.263
pmid: 19827093
|
[17] |
Conry R M, LoBuglio A F, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Research, 1995, 55(7): 1397-1400.
pmid: 7882341
|
[18] |
Sebastian M, Papachristofilou A, Weiss C, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 2014, 14(1): 1-10.
doi: 10.1186/1471-2407-14-1
|
[19] |
Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585(7823): 107-112.
doi: 10.1038/s41586-020-2537-9
|
[20] |
Cafri G, Gartner J J, Zaks T, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. The Journal of Clinical Investigation, 2020, 130(11): 5976-5988.
doi: 10.1172/JCI134915
|
[21] |
Burris Howard A, Patel Manish R, Cho Daniel C, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Journal of Clinical Oncology, 2019, 37(15_suppl): 2523.
doi: 10.1200/JCO.2019.37.15_suppl.2523
|
[22] |
Hou X C, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021, 6(12): 1078-1094.
doi: 10.1038/s41578-021-00358-0
|
[23] |
Schumacher T N, Schreiber R D. Neoantigens in cancer immunotherapy. Science, 2015, 348(6230): 69-74.
doi: 10.1126/science.aaa4971
pmid: 25838375
|
[24] |
Bauer T, Patel M, Jimeno A, et al. A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36, for intratumoral injection alone and in combination with immune checkpoint blockade. Cancer Research, 2019, 79(13) : CT210.
|
[25] |
Patel M, Bauer T, Jimeno A, et al. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. Journal of Clinical Oncology, 2020, 38(15_suppl): 3092.
doi: 10.1200/JCO.2020.38.15_suppl.3092
|
[26] |
Rurik J G, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science, 2022, 375(6576): 91-96.
doi: 10.1126/science.abm0594
pmid: 34990237
|
[27] |
Kramps T, Elbers K. Introduction to RNA vaccines. Methods in Molecular Biology (Clifton, N J), 2017, 1499: 1-11.
|
[28] |
Yang J L, Zhu J F, Sun J J, et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Molecular Therapy-Nucleic Acids, 2022, 30: 184-197.
doi: 10.1016/j.omtn.2022.09.010
|
[29] |
Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Therapy, 2007, 14(15): 1175-1180.
doi: 10.1038/sj.gt.3302964
pmid: 17476302
|
[30] |
Lindsay K E, Bhosle S M, Zurla C, et al. Visualization of early events in mRNA vaccine delivery in non-human Primates via PET-CT and near-infrared imaging. Nature Biomedical Engineering, 2019, 3(5): 371-380.
doi: 10.1038/s41551-019-0378-3
pmid: 30936432
|
[31] |
Liang F, Lindgren G, Lin A, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus macaques. Molecular Therapy, 2017, 25(12): 2635-2647.
doi: 10.1016/j.ymthe.2017.08.006
|
[32] |
Zhang Z K, Ohto U, Shibata T, et al. Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity, 2016, 45(4): 737-748.
doi: S1074-7613(16)30380-6
pmid: 27742543
|
[33] |
Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nature Structural & Molecular Biology, 2015, 22(2): 109-115.
doi: 10.1038/nsmb.2943
|
[34] |
Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 2004, 303(5663): 1526-1529.
doi: 10.1126/science.1093620
pmid: 14976262
|
[35] |
Weide B, Carralot J P, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy (Hagerstown, Md: 1997), 2008, 31(2): 180-188.
|
[36] |
Wang Z Q, Cui K, Costabel U, et al. Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic. Exploration, 2022, 2(5): 20210082.
|
[37] |
Wang G L, Uludag H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opinion on Drug Delivery, 2008, 5(5): 499-515.
doi: 10.1517/17425247.5.5.499
pmid: 18491978
|
[38] |
Locatelli E, Franchini M C. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. Journal of Nanoparticle Research, 2012, 14(12): 1316.
doi: 10.1007/s11051-012-1316-4
|
[39] |
Fornaguera C, Castells-Sala C, Borrós S. Unraveling polymeric nanoparticles cell uptake pathways: two decades working to understand nanoparticles journey to improve gene therapy. Advances in Experimental Medicine and Biology, 2020, 1288: 117-138.
doi: 10.1007/5584_2019_467
pmid: 31916235
|
[40] |
Tomalia D A. The dendritic state. Materials Today, 2005, 8(3): 34-46.
|
[41] |
Mbatha L S, Maiyo F, Daniels A, et al. Dendrimer-coated gold nanoparticles for efficient folate-targeted mRNA delivery in vitro. Pharmaceutics, 2021, 13(6): 900.
doi: 10.3390/pharmaceutics13060900
|
[42] |
Abedi-Gaballu F, Dehghan G, Ghaffari M, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Applied Materials Today, 2018, 12: 177-190.
doi: 10.1016/j.apmt.2018.05.002
pmid: 30511014
|
[43] |
Zhang D P, Atochina-Vasserman E N, Maurya D S, et al. One-component multifunctional sequence-defined ionizable amphiphilic Janus dendrimer delivery systems for mRNA. Journal of the American Chemical Society, 2021, 143(31): 12315-12327.
doi: 10.1021/jacs.1c05813
pmid: 34324336
|
[44] |
Kowalski P S, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Molecular Therapy, 2019, 27(4): 710-728.
doi: S1525-0016(19)30053-X
pmid: 30846391
|
[45] |
Zhao J, Weng G J, Li J J, et al. Polyester-based nanoparticles for nucleic acid delivery. Materials Science & Engineering C, Materials for Biological Applications, 2018, 92: 983-994.
|
[46] |
Trivedi R, Kompella U B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (London, England), 2010, 5(3): 485-505.
doi: 10.2217/nnm.10.10
|
[47] |
Mandal A, Bisht R, Rupenthal I D, et al. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. Journal of Controlled Release, 2017, 248: 96-116.
doi: S0168-3659(17)30017-2
pmid: 28087407
|
[48] |
Gill K K, Kaddoumi A, Nazzal S. PEG-lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication. Journal of Drug Targeting, 2015, 23(3): 222-231.
doi: 10.3109/1061186X.2014.997735
pmid: 25547369
|
[49] |
Miyazaki T, Uchida S, Nagatoishi S, et al. Polymeric nanocarriers with controlled chain flexibility boost mRNA delivery in vivo through enhanced structural fastening. Advanced Healthcare Materials, 2020, 9(16): 2000538.
|
[50] |
Jhaveri A M, Torchilin V P. Multifunctional polymeric micelles for delivery of drugs and siRNA. Frontiers in Pharmacology, 2014, 5: 77.
doi: 10.3389/fphar.2014.00077
pmid: 24795633
|
[51] |
Li Y M, Wei S T, Sun Y H, et al. Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis. Drug Delivery and Translational Research, 2021, 11(6): 2520-2529.
doi: 10.1007/s13346-021-01037-x
pmid: 34331261
|
[52] |
O’Keeffe Ahern J, A S, Zhou D Z, et al. Brushlike cationic polymers with low charge density for gene delivery. Biomacromolecules, 2018, 19(5): 1410-1415.
doi: 10.1021/acs.biomac.7b01267
pmid: 29125281
|
[53] |
Ferrari R, Sponchioni M, Morbidelli M, et al. Polymer nanoparticles for the intravenous delivery of anticancer drugs: the checkpoints on the road from the synthesis to clinical translation. Nanoscale, 2018, 10(48): 22701-22719.
doi: 10.1039/c8nr05933k
pmid: 30512025
|
[54] |
Qian C G, Chen Y L, Feng P J, et al. Conjugated polymer nanomaterials for theranostics. Acta Pharmacologica Sinica, 2017, 38(6): 764-781.
doi: 10.1038/aps.2017.42
|
[55] |
Tan L, Zheng T, Li M, et al. Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates. Drug Delivery and Translational Research, 2020, 10(3): 678-689.
doi: 10.1007/s13346-020-00725-4
pmid: 32048201
|
[56] |
Verma G, Rajagopalan M D, Valluru R, et al. Nanoparticles: A novel approach to target tumors. Nano-and Microscale Drug Delivery Systems. Amsterdam: Elsevier, 2017: 113-129.
|
[57] |
Sharifnia Z, Bandehpour M, Hamishehkar H, et al. In-vitro transcribed mRNA delivery using PLGA/PEI nanoparticles into human monocyte-derived dendritic cells. Iranian Journal of Pharmaceutical Research: IJPR, 2019, 18(4): 1659-1675.
|
[58] |
Khurana A, Allawadhi P, Khurana I, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 2021, 38: 101142.
doi: 10.1016/j.nantod.2021.101142
|
[59] |
苗佳颖, 陆伟. 应用于mRNA疫苗的非病毒载体递送系统研究进展. 药学进展, 2022, 46(2): 84-92.
|
|
Miao J Y, Lu W. Research progress of non-viral vector delivery system for mRNA vaccine. Progress in Pharmaceutical Sciences, 2022, 46(2): 84-92.
|
[60] |
Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 2015, 217: 345-351.
doi: 10.1016/j.jconrel.2015.08.007
pmid: 26264835
|
[61] |
Moyer T J, Zmolek A C, Irvine D J. Beyond antigens and adjuvants: formulating future vaccines. The Journal of Clinical Investigation, 2016, 126(3): 799-808.
doi: 10.1172/JCI81083
|
[62] |
Sebastian M, Schröder A, Scheel B, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68(5): 799-812.
doi: 10.1007/s00262-019-02315-x
|
[63] |
Walsh E E, Frenck R W Jr, Falsey A R, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. The New England Journal of Medicine, 2020, 383(25): 2439-2450.
doi: 10.1056/NEJMoa2027906
pmid: 33053279
|
[64] |
Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b 2 mRNA COVID-19 vaccine. The New England Journal of Medicine, 2020, 383(27): 2603-2615.
doi: 10.1056/NEJMoa2034577
|
[65] |
Anderson E J, Rouphael N G, Widge A T, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. The New England Journal of Medicine, 2020, 383(25): 2427-2438.
doi: 10.1056/NEJMoa2028436
|
[66] |
Wilson B, Geetha K M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. Journal of Drug Delivery Science and Technology, 2022, 74: 103553.
doi: 10.1016/j.jddst.2022.103553
|
[67] |
Tenchov R, Bird R, Curtze A E, et al. Lipid Nanoparticles:from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano, 2021, 15(11): 16982-17015.
doi: 10.1021/acsnano.1c04996
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|